tetano
Editor, Senior Moderator
Respirol Case Rep
. 2022 Jul 4;10(8):e0995.
doi: 10.1002/rcr2.995. eCollection 2022 Aug.
Two cases of acute respiratory failure following SARS-CoV-2 vaccination in post-COVID-19 pneumonia
Tomohiro Bando[SUP] 1 [/SUP], Reoto Takei[SUP] 1 [/SUP], Yoshikazu Mutoh[SUP] 2 [/SUP], Hajime Sasano[SUP] 1 [/SUP], Yasuhiko Yamano[SUP] 1 [/SUP], Toshiki Yokoyama[SUP] 1 [/SUP], Toshiaki Matsuda[SUP] 1 [/SUP], Kensuke Kataoka[SUP] 1 [/SUP], Tomoki Kimura[SUP] 1 [/SUP], Yasuhiro Kondoh[SUP] 1 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is a very effective method of preventing infection and is recommended for people having recovered from coronavirus disease 2019 (COVID-19). In this novel case report, we describe two patients with post-COVID-19 pneumonia who experienced acute respiratory failure and new bilateral ground-glass opacities several days after receiving SARS-CoV-2 vaccination. Both patients were treated with methylprednisolone pulse therapy and recovered from the disease successfully. Indeed, post-COVID-19 patients can gain benefits from the vaccine, but vaccination at the early stage of recovery from COVID-19 might be a risk for certain populations. These cases highlight a potential association between vaccination, interstitial lung disease and worsening of post-COVID-19 pneumonia. Further investigation and research examining the relationship between the timing of SARS-CoV-2 vaccination and potential risks in post-COVID-19 patients is recommended.
Keywords: COVID‐19; acute exacerbation of interstitial lung disease; interstitial lung disease; vaccination.
. 2022 Jul 4;10(8):e0995.
doi: 10.1002/rcr2.995. eCollection 2022 Aug.
Two cases of acute respiratory failure following SARS-CoV-2 vaccination in post-COVID-19 pneumonia
Tomohiro Bando[SUP] 1 [/SUP], Reoto Takei[SUP] 1 [/SUP], Yoshikazu Mutoh[SUP] 2 [/SUP], Hajime Sasano[SUP] 1 [/SUP], Yasuhiko Yamano[SUP] 1 [/SUP], Toshiki Yokoyama[SUP] 1 [/SUP], Toshiaki Matsuda[SUP] 1 [/SUP], Kensuke Kataoka[SUP] 1 [/SUP], Tomoki Kimura[SUP] 1 [/SUP], Yasuhiro Kondoh[SUP] 1 [/SUP]
Affiliations
- PMID: 35814194
- PMCID: PMC9251883
- DOI: 10.1002/rcr2.995
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is a very effective method of preventing infection and is recommended for people having recovered from coronavirus disease 2019 (COVID-19). In this novel case report, we describe two patients with post-COVID-19 pneumonia who experienced acute respiratory failure and new bilateral ground-glass opacities several days after receiving SARS-CoV-2 vaccination. Both patients were treated with methylprednisolone pulse therapy and recovered from the disease successfully. Indeed, post-COVID-19 patients can gain benefits from the vaccine, but vaccination at the early stage of recovery from COVID-19 might be a risk for certain populations. These cases highlight a potential association between vaccination, interstitial lung disease and worsening of post-COVID-19 pneumonia. Further investigation and research examining the relationship between the timing of SARS-CoV-2 vaccination and potential risks in post-COVID-19 patients is recommended.
Keywords: COVID‐19; acute exacerbation of interstitial lung disease; interstitial lung disease; vaccination.